Positron Emission Tomography of CD47/SIRPα Axis and Image-Informed Therapeutic Design
Preprint
Abstract
CD47/SIRPα immune axis is of substantial clinical interest for innate cancer immunotherapy. Development on this axis has largely focused on monoclonal antibody agents and combination therapy strategies. Clinical use is challenging due to dose limiting side effects and severe anemia. Better understanding of the whole-body dynamics of CD47/SIRPα can be used to improve the developmental and therapeutic strategies targeting this axis. Herein, we developed anti-CD47 and anti-SIRPα radiotracers with good yields and stability. CD47/SIRPα biodistribution showed consistent whole-body results in healthy and colorectal cancer (CT26) allograft mice, demonstrating significant uptake in normal organs liver and spleen in addition to tumor accumulation of these agents. Enhancing immunogenicity via low-dose radiotherapy had no impact on over-all biodistribution but caused small, significant changes for anti-SIRPα tumor uptake. Antibody PEGylation of the anti-SIRPα tracer was further able to modify the whole-body distribution and reduce splenic uptake. These findings suggest that SIRPα targeted agents may benefit from co-therapies and drug delivery systems to optimize tumor uptake. Our work highlights the importance of in vivo molecular imaging in addition to in vitro and ex vivo assays when evaluating therapeutic designs.Keywords
This publication has 45 references indexed in Scilit:
- “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunityCancer Communications, 2024
- Don't eat me/eat me signals as a novel strategy in cancer immunotherapyHeliyon, 2023
- Stealth nanoparticles in oncology: Facing the PEG dilemmaJournal of Controlled Release, 2022
- CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategiesClinical and Translational Medicine, 2022
- Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion studyThe Lancet Oncology, 2021
- Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapyCancer Letters, 2021
- CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and PhagocytosisImmunity, 2020
- CD47 blockade alleviates acute rejection of allogeneic mouse liver transplantation by reducing ischemia/reperfusion injuryBiomedicine & Pharmacotherapy, 2020
- PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved DrugsJournal of Pharmaceutical Sciences, 2016
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009